Clinical OMICS

JAN-FEB 2019

Healthcare magazine for research scientists, labs, pathologists, hospitals, cancer centers, physicians and biopharma companies providing news articles, expert interviews and videos about molecular diagnostics in precision medicine

Issue link: https://clinicalomics.epubxp.com/i/1071882

Contents of this Issue

Navigation

Page 5 of 51

www.clinicalomics.com January/February 2019 Clinical OMICs 4 Oral Microbiome Biomarkers Show Potential for Arthritis Screening New research by a team of Chinese inves- tigators published in the journal Nature identified eight oral bacterial biomarkers to differentiate rheumatoid arthritis (RA) from osteoarthritis (OA) that could provide the information needed for the develop- ment of non-invasive arthritis screening. "Many clinical studies have shown that RA and OA may be associated with oral microbiota and are affected by it," the au- thors wrote. "However, recent findings suggest that OA may also be regulated by the mi- crobiome, but there are very few studies describing the potential effects of oral microbiota in patients with OA." For this study, the in- vestigators compared the oral microbiota profiles of 110 RA patients, 67 OA patients and 155 healthy subjects, which showed significant differenc- es between RA patients, OA patients and the healthy con- trols. n New Study to Examine Treatment Resistance in EGRF-Positive Lung Cancer Two patient-driven cancer organizations focused on lung cancer and Champions Oncology have launched a new research initiative aimed at developing a better understanding of the unique character- istics of epidermal growth factor receptor (EGFR) positive lung cancer. The new study was conceived by pa- tient-centric organization the Addario Lung Cancer Foundation (ALCF) and the EGFR Resisters, which has established a collaboration between the Addario Lung Cancer Medical Institute (ALCMI), and a leading researcher in EGFR mutant lung cancer, Pasi A. Jänne, M.D., Ph.D., of Dana-Farber Cancer Institute. Champions Oncology will use tissue and pleural samples to create models of tumors in mice with limited immune function. Champions will then make the mouse models available to researchers worldwide to foster and broaden EGRF mutant research aimed at why some pa- tients with EGFR positive lung cancer de- velop resistance to treatment. "This study provides an opportunity to change EGFR positive lung cancer into a manageable, chronic disease," said Jänne. n Illumina Leads $18M Investment Round in French PCR Firm French digital PCR company Still Technologies announced it closed a €16 million ($18.1 million) Series A financing round led by Illumina Ventures, joined by Kurma Partners, LBO France, BNP Paribas Développement, Paris Saclay Seeds, and Idinvest Partners. Stilla was founded eight years ago as a spinout of the École Polytechnique Université Paris-Saclay and unveiled its Naica digital PCR (dPCR) platform for commercial sale in 2016. The company's technology leverages microfluidic handling, which integrates dPRC on a single consumable. "This additional financing will enable Stilla to accelerate the sales of the Naica System, launch our 2nd generation solution, and begin clinically validating panels to be run on the system, with an initial focus in the field of oncology," said Rémi Dangla, CEO and co-founder of Stilla Technologies, in a press release announcing the investment round. n Kateryna Kon /Science Photo Library/ Getty Images volschenkh / E+ / Getty Images Sebastian Kaulitzki / Science Photo / Getty Images

Articles in this issue

Links on this page

Archives of this issue

view archives of Clinical OMICS - JAN-FEB 2019